MarginsXMarginsX
Home › Markets › Health Care › CGEM

Cullinan Therapeutics Inc. (CGEM)

CGEM trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.50
-7.59% on the day
Market cap
$616.7M
Small cap
Revenue · 2022
$0
-100.0% on 2021
Net income · 2022
$111.2M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1789972/000095017023006839/0000950170-23-006839-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerCGEM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001789972
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2022

LineValue
Revenue$0
Net income$111.2M
Operating income$144.6M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$156.2M
Total assets$561.1M
P/E (computed)5.5×
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
6.4 months
$88.3M cash at September 30, 2026
Share count, 1 year
+9.9%
2025-10-31 to 2026-11-04 · +51.8% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$10.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$88.3M cash; operating cash flow -$41.4M a quarter.Report 2026-09-30
Shares outstanding64,920,924 (2026-11-04); 59,076,259 a year earlier; 42,780,644 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-04-28
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $13.3M, sold $2.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$49.4M-$43.1M$88.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$53.7M-$38.2M$78.6MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$49.7M-$46.0M$75.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$50.7M-$38.1M$88.3MNo debt tagsNeeds four quarters10-K 2026-03-10
Q3 2025
2025-09-30
Not filed-$50.6M-$36.9M$103.3MNo debt tagsNeeds four quarters10-Q 2025-11-06
Q2 2025
2025-06-30
Not filed-$70.1M-$57.6M$72.8MNo debt tagsNeeds four quarters10-Q 2025-08-07
Q1 2025
2025-03-31
Not filed-$48.5M-$43.2M$76.7MNo debt tagsNeeds four quarters10-Q 2025-05-08
Q4 2024
2024-12-31
Not filed-$47.6M-$36.6M$83.0MNo debt tagsNeeds four quarters10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-04-28
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 471 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.1%
1 month-27.1%
3 months-47.7%
Year to date-0.7%
1 year+24.3%
From 52-week high-55.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SRZNSurrozen Inc.$32.32+2.25%$616.1M
FDMT4D Molecular Therapeutics Inc.$11.29-7.69%$636.5M
BBTXBambusa Therapeutics Inc.$15.98-0.68%$645.4M
DBVTDBV Technologies S.A.$10.27-6.76%$645.8M
ATTOAttovia Therapeutics Inc.$14.72-2.68%$673.1M
SANASana Biotechnology Inc.$1.88-6.93%$563.3M
IAMIambic Therapeutics Inc.$11.85-9.54%$561.7M
DNAGinkgo Bioworks Holdings Inc.$8.50-11.55%$551.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier